NCT05430828 Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
| NCT ID | NCT05430828 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Federico II University |
| Condition | Hypercholesterolemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2020-03-07 |
| Primary Completion | 2022-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2020-03-07 with a primary completion date of 2022-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.
Eligibility Criteria
Inclusion Criteria: * Patients under PCSK9 inhibitor treatment. Exclusion Criteria: * Age \< 18 years o \> 80 years; * Patients who refuse to participate and to sign informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05430828 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hypercholesterolemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05430828 currently recruiting?
Yes, NCT05430828 is actively recruiting participants. Contact the research team at fpperron@unina.it for enrollment information.
Where is the NCT05430828 trial being conducted?
This trial is being conducted at Arzignano, Italy, Bari, Italy, Caserta, Italy, Catanzaro, Italy and 11 additional locations.
Who is sponsoring the NCT05430828 clinical trial?
NCT05430828 is sponsored by Federico II University. The trial plans to enroll 5,000 participants.